Skip to main content

Table 2 Clinical and Laboratory Parameters of the Radiographic Axial Spondyloarthritis Patients and the Healthy Donors

From: Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-α therapy effectiveness

 

r-axSpA patients (n = 30)

Healthy Donors (n = 32)

P

Clinical parameters

 Women/men, n/n

5/25

10/22

0.180

 Age, y

46.40 ± 2.45

41.06 ± 1.77

0.080

 BASDAI

4.42 ± 0.45

 

 BASFI

4.73 ± 0.61

 

 BASMI

3.22 ± 0.31

 

 mSASSS

19.16 ± 3.86

 

 Disease duration, y

13.23 ± 2.07

 

 Extra-articular manifestations

 ➣ Uveitis

0/30

0/32

 

 ➣ Psoriasis

0/30

0/32

 

 ➣ IBD

0/30

0/32

 

Laboratory parameters

 HLA-B27 (%)

26/30 (86.67%)

 

 CRP, nmol/L

122.57 ± 31.38

13.62 ± 3.25

< 0.001

 ESR, mm/h

19.84 ± 4.09

7.48 ± 1.00

0.006

 TNF-α, pg/mL

10.89 ± 1.82

4.02 ± 1.20

0.021

 IL-1β, pg/mL

2.46 ± 0.22

1.57 ± 0.27

0.047

Treatments

 NSAIDs (%)

28/30 (93.33%)

 

 Sulfasalazine (%)

2/30 (6.67%)

 
  1. Values are presented as mean ± SEM. The data were analyzed using an Independent Samples t test or a Mann-Whitney U test to evaluate statistical significance between r-axSpA patients and healthy donors. Non-normally distributed data. BASDAI indicates Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functionality Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leukocyte antigen; IBD, inflammatory bowel disease; IL, interleukin; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; r-axSpA, radiographic axial spondyloarthritis; TNF, tumor necrosis factor